Abstract
Emerging evidence suggests a class of non-coding RNAs termed microRNAs (miRNAs) play a key role in cancer. Since their original discovery in C. elegans in 1993 it has become evident that miRNAs are responsible for an entirely new mechanism of posttranscriptional gene regulation. miRNA expression is widespread in mammalian cells and notably altered in several cancer types. miRNA expression patterns correlate with several aspects of tumorigenesis and miRNA loci have been mapped to frequently altered cancerassociated genomic regions. Inhibition or augmentation of miRNA expression in cancer cells impacts gene expression and affects cell proliferation and survival. Hence, cancer-associated miRNAs may be regarded as a new class of non-coding tumour suppressors and oncogenes capable of regulating several key signalling pathways.
Current Pharmaceutical Biotechnology
Title: MicroRNAs in Tumorigenesis
Volume: 8 Issue: 6
Author(s): Kai Ove Skaftnesmo, Lars Prestegarden, David R. Micklem and James B. Lorens
Affiliation:
Keywords: RNA, microRNA, cancer
Abstract: Emerging evidence suggests a class of non-coding RNAs termed microRNAs (miRNAs) play a key role in cancer. Since their original discovery in C. elegans in 1993 it has become evident that miRNAs are responsible for an entirely new mechanism of posttranscriptional gene regulation. miRNA expression is widespread in mammalian cells and notably altered in several cancer types. miRNA expression patterns correlate with several aspects of tumorigenesis and miRNA loci have been mapped to frequently altered cancerassociated genomic regions. Inhibition or augmentation of miRNA expression in cancer cells impacts gene expression and affects cell proliferation and survival. Hence, cancer-associated miRNAs may be regarded as a new class of non-coding tumour suppressors and oncogenes capable of regulating several key signalling pathways.
Export Options
About this article
Cite this article as:
Skaftnesmo Ove Kai, Prestegarden Lars, Micklem R. David and Lorens B. James, MicroRNAs in Tumorigenesis, Current Pharmaceutical Biotechnology 2007; 8 (6) . https://dx.doi.org/10.2174/138920107783018390
DOI https://dx.doi.org/10.2174/138920107783018390 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cationic Liposome Mediated Delivery of FUS1 and hIL-12 Coexpression Plasmid Demonstrates Enhanced Activity against Human Lung Cancer
Current Cancer Drug Targets In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry Four-Component Synthesis of 1,2-Dihydropyridine Derivatives and their Evaluation as Anticancer Agents
Medicinal Chemistry Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Current Cancer Drug Targets Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc
Anti-Cancer Agents in Medicinal Chemistry NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry SRC: Regulation, Role in Human Carcinogenesis and Pharmacological Inhibitors
Current Pharmaceutical Design The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma
Current Drug Delivery Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion
Current Drug Targets Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
Current Molecular Medicine Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Diastereoselective Synthesis of Dispiropseudoindoxyls and Preparation of 9-Oxopyrrolo[ 1,2-α]Indoles
Current Organic Synthesis